サカモト　ユウマ   Yuma Sakamoto   坂本　祐真    所属   川崎医科大学  医学部 基礎医学　免疫学    職種   助教
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
掲載誌名	正式名：British journal of haematology 略　 称：Br J Haematol ISSNコード：13652141/00071048
掲載区分	国外
巻・号・頁	195(4),pp.571-584
著者・共著者	Yuma Sakamoto, Takashi Ishida, Ayako Masaki, Takayuki Murase, Morishige Takeshita, Reiji Muto, Hiromi Iwasaki, Asahi Ito, Shigeru Kusumoto, Nobuaki Nakano, Masahito Tokunaga, Kentaro Yonekura, Yukie Tashiro, Shinsuke Iida, Atae Utsunomiya, Ryuzo Ueda, Hiroshi Inagaki
発行年月	2021/11
概要	Adult T-cell leukaemia/lymphoma (ATL) patients have a poor prognosis. Here, we investigated the impact of TP53 gene mutations on prognosis of ATL treated in different ways. Among 177 patients, we identified 47 single nucleotide variants or insertion-deletions (SNVs/indels) of the TP53 gene in 37 individuals. TP53 copy number variations (CNVs) were observed in 38 patients. Altogether, 67 of 177 patients harboured TP53 SNVs/indels or TP53 CNVs, and were categorized as having TP53 mutations. In the entire cohort, median survival of patients with and without TP53 mutations was 1·0 and 6·7 years respectively (P < 0·001). After allogeneic haematopoietic stem cell transplantation (HSCT), median survival of patients with (n = 16) and without (n = 29) TP53 mutations was 0·4 years and not reached respectively (P = 0·001). For patients receiving mogamulizumab without allogeneic HSCT, the median survival from the first dose of antibody in patients with TP53 mutations (n = 27) was only 0·9 years, but 5·1 years in those without (n = 42; P < 0·001). Thus, TP53 mutations are associated with unfavourable prognosis of ATL, regardless of treatment strategy. The establishment of alternative modalities to overcome the adverse impact of TP53 mutations in patients with ATL is required.
DOI	10.1111/bjh.17749
PMID	34405395